Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization -44% Improvement Relative Risk Case 10% HCQ for COVID-19  Kamstrup et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 60,334 patients in Denmark Higher hospitalization with HCQ (not stat. sig., p=0.25) c19hcq.org Kamstrup et al., Int. J. Infectious Di.., Jun 2021 Favors HCQ Favors control

Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

Kamstrup et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.05.076
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective HCQ users in Denmark, not showing a significant difference, however authors do not adjust for the very different baseline risk for systemic autoimmune disease patients.
Authors appear unaware of research in the area, for example saying that "currently, no obvious connection exists between a known rheumatological disorder and the risk of contracting SARS-CoV-2". Many papers show that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, e.g., Ferri et al. show OR 4.42, p<0.001 Ferri.
Supplementary data is not currently available.
This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.
risk of hospitalization, 44.0% higher, OR 1.44, p = 0.25, treatment 5,488, control 54,846, RR approximated with OR.
risk of case, 10.0% lower, HR 0.90, p = 0.23, treatment 188 of 5,488 (3.4%), control 2,040 of 54,846 (3.7%), NNT 340, adjusted Cox proportional hazards regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kamstrup et al., 1 Jun 2021, retrospective, population-based cohort, Denmark, peer-reviewed, 21 authors.
This PaperHCQAll
Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
Peter Kamstrup, Pradeesh Sivapalan, Josefin Eklöf, Nils Hoyer, Charlotte Suppli Ulrik, Lars Pedersen, Therese S Lapperre, Zitta Barrella Harboe, Uffe Bodtger, Rasmus Dahlin Bojesen, Kjell E J Håkansson, Casper Tidemandsen, Karin Armbruster, Andrea Browatzki, Howraman Meteran, Christian Niels Meyer, Kristoffer Grundtvig Skaarup, Mats Christian Højbjerg Lassen, Jens D Lundgren, Tor Biering-Sørensen, Jens-Ulrik Jensen
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.05.076
Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of verified infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) compared with matched controls. Methods: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e., both during and before SARS-CoV-2 was confirmed in Denmark), matched by age and sex with controls, was studied. Data were collected using the Danish national registries, which contain complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection. Results: In total, 5488 hydroxychloroquine users were matched with 54,486 non-users. At baseline, the groups differed in terms of diagnoses of pulmonary disease, cardiovascular disease, renal disease, gastrointestinal/metabolic disease and dementia, as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indications was not associated with any change in confirmed SARS-CoV-2 (hazard ratio 0.90, 95% confidence interval 0.76-1.07). This result was robust in the propensity-score-matched sensitivity analysis. Conclusion: This study, which is the largest to date to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2.
Conflict of interest PS reports personal fees from Boehringer Ingelheim outside the submitted work. CT reports personal fees from TEVA outside the submitted work. KEJH reports personal fees from AstraZeneca, personal fees from TEVA and personal fees from Chiesi outside the submitted work. CSU reports personal fees from AstraZeneca; personal fees and non-financial support from GSK; personal fees from Chiesi; personal fees from TEVA; grants and personal fees from Sanofi Genzyme; personal fees from Orion Pharma; personal fees from Actelion; grants and personal fees from Boehringer-Ingelheim; grants and personal fees from Mundipharma; and grants, personal fees and non-financial support from Novartis outside the submitted work. TBS reports personal fees from Amgen, grants from Sanofi Pasteur, grants from GE Healthcare, personal fees from Sanofi Pasteur, and personal fees from Novartis outside the submitted work. All other authors declare no competing interests. Data sharing Statistical source code used for generation of the results can be obtained via the corresponding author. Source data collected for this study will not be made available to others due to Danish legislation regarding data sharing on population data. However, Danish citizens who have a legitimate reason can apply for access to the data via the Danish National Health Authority (https:// sundhedsdatastyrelsen.dk/da/forskerservice/ansog-om-data). The study protocol is available at http://coptrin.dk/wp-content/..
References
Abd-Elsalam, Esmail, Khalaf, Abdo, Medhat et al., Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study, Am J Trop Med Hyg
Abella, Jolkovsky, Biney, Uspal, Hyman et al., Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial, JAMA Intern Med
Bae, Ghang, Kim, Lim, Yun et al., Recent hydroxychloroquine use is not significantly associated with positive PCR results for SARS-CoV-2: a nationwide observational study in South Korea, Viruses
Barnabas, Brown, Bershteyn, Karita, Johnston et al., Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial, Ann Intern Med
Bartoszko, Siemieniuk, Kum, Qasim, Zeraatkar et al., Prophylaxis for COVID-19: living systematic review and network meta-analysis, BMJ, doi:10.1136/bmj.n949
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19, N Engl J Med
Elm, Altman, Egger, Pocock, Gotzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, J Clin Epidemiol
Ferreira, Oliveira, Bettencourt, Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection, J Med Virol
García-Albéniz, Jd, Polo, Morales-Asencio, Hernán, Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19, medRxiv
Gendelman, Amital, Bragazzi, Watad, Chodick, Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis, Autoimmun Rev
Group, Horby, Mafham, Linsell, Bell et al., Effect of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med
Ioannou, Locke, Green, Berry, Hare et al., Risk factors for hospitalization, mechanical ventilation, or death among 10131 US veterans with SARS-CoV-2 infection, JAMA Netw Open
Jung, Kim, Kim, Choi, Chung et al., Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study, Clin Microbiol Infect
Kamstrup, Sivapalan, Eklöf, None, International Journal of Infectious Diseases
Kamstrup, Sivapalan, Eklöf, None, International Journal of Infectious Diseases
Lamontagne, Agoritsas, Siemieniuk, Rochwerg, Bartoszko et al., A living WHO guideline on drugs to prevent COVID-19, BMJ
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Mitjà, Corbacho-Monné, Ubals, Alemany, Suñer et al., A clusterrandomized trial of hydroxychloroquine for prevention of COVID-19, N Engl J Med
Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy, Repurposed antiviral drugs for COVID-19 -Interim WHO Solidarity Trial Results, N Engl J Med
Ponticelli, Moroni, Hydroxychloroquine in systemic lupus erythematosus (SLE), Expert Opin Drug Saf
Pottegard, Schmidt, Wallach-Kildemoes, Sorensen, Hallas et al., Data resource profile: the Danish national prescription registry, Int J Epidemiol
Quan, Sundararajan, Halfon, Fong, Burnand et al., Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, Med Care
Rajasingham, Bangdiwala, Nicol, Skipper, Pastick et al., Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial, Clin Infect Dis
Reilev, Kristensen, Pottegard, Lund, Hallas et al., Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort, Int J Epidemiol
Ruiz-Irastorza, Ramos-Casals, Brito-Zeron, Khamashta, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Ann Rheum Dis
Schmidt, Pedersen, Sorensen, The Danish Civil Registration System as a tool in epidemiology, Eur J Epidemiol
Schmidt, Schmidt, Sandegaard, Ehrenstein, Pedersen et al., The Danish National Patient Registry: a review of content, data quality, and research potential, Clin Epidemiol
Self, Semler, Leither, Casey, Angus et al., Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial, JAMA
Singh, Ryan, Kredo, Chaplin, Fletcher, Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19, Cochrane Database Syst Rev
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ
Voldstedlund, Haarh, Molbak, MiBa board of representatives. The Danish microbiology database (MiBa) 2010 to 2013, Euro Surveill
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit